Weight Loss
Mfg : Novo NordiskOnce-Daily Oral GLP-1 Weight Loss Treatment
Once-Daily Oral GLP-1 Weight Loss Treatment Wegovy Tablets contain semaglutide, a prescription GLP-1 medication that helps adults manage their weight by regulating appetite and reducing food intake. When combined with a reduced-calorie diet and regular physical activity, Wegovy supports medically supervised weight loss and long-term weight management.
Convenient Oral Weight Loss Medication A once-daily tablet that offers an alternative to injectable GLP-1 treatments, helping control hunger, reduce food intake, and support weight loss.
Flexible Dosage Options Available in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths, allowing healthcare providers to gradually adjust dosing based on the prescribed treatment schedule and individual patient needs.
Personalized Medical Evaluation Treatment begins with an evaluation by a licensed healthcare provider to determine eligibility, review medical history, and establish an appropriate prescription and dosing plan.
FDA-Approved Medication by Novo Nordisk Wegovy is a prescription GLP-1 medication developed by Novo Nordisk to support chronic weight management in eligible patients when used alongside healthy lifestyle changes.
Disclaimer: The FDA may not have evaluated this product for safety, effectiveness, or quality.Maximum Doses: 4
Per Dose $ 00.00
Total Price
Wegovy Tablets contain semaglutide, a prescription GLP-1 receptor agonist that helps regulate appetite, reduce hunger, and support long-term weight management. This once-daily oral medication offers an alternative to injectable weight loss treatments for eligible adults. When combined with a reduced-calorie diet and increased physical activity, Wegovy can help patients achieve and maintain meaningful weight loss under medical supervision. This information is intended for educational purposes and does not replace professional medical advice.
Product Name: Wegovy Tablets
Medication Category: Prescription GLP-1 Weight Management
Active Ingredient: Semaglutide
Available Strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg
Dosage Form: Oral Tablet
Administration: Once daily by mouth
Manufacturer: Novo Nordisk
Prescription Requirement: Valid prescription from a licensed healthcare provider
Wegovy contains semaglutide, which mimics the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in appetite regulation. By activating GLP-1 receptors, semaglutide helps reduce hunger, increase feelings of fullness, and decrease overall food intake. These effects can support weight loss when treatment is combined with healthy eating habits and regular physical activity.
Take Wegovy Tablets once daily in the morning on an empty stomach with no more than 4 ounces of plain water. Swallow each tablet whole without crushing, splitting, or chewing it. Wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications. Follow your healthcare providers prescribed dosing instructions and do not adjust your dose without medical guidance.
Convenient Once-Daily Tablet: Provides an oral prescription GLP-1 treatment option for patients who prefer tablets rather than injections.
Appetite and Hunger Management: Helps regulate appetite, reduce food intake, and promote feelings of fullness to support weight management.
Multiple Dosage Strengths: Available in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths to accommodate gradual dose adjustments and individualized treatment plans.
Long-Term Weight Management: Designed to support ongoing weight management when combined with a reduced-calorie diet and increased physical activity.
Medically Supervised Treatment: Requires a healthcare providers evaluation, prescription, and ongoing monitoring to assess treatment response and tolerability.
Manufactured by Novo Nordisk: Developed by Novo Nordisk, a pharmaceutical manufacturer with extensive experience in GLP-1 medications.
Adults with obesity who are seeking a medically supervised prescription weight management treatment.
Adults who are overweight and have at least one weight-related medical condition, such as high blood pressure, high cholesterol, or type 2 diabetes.
Patients who prefer a once-daily oral medication instead of an injectable GLP-1 treatment.
Individuals who have experienced difficulty achieving or maintaining weight loss through diet and exercise alone.
Patients who meet the prescribing criteria following a medical evaluation by a licensed healthcare provider.
Wegovy Tablets are prescription medications that require a medical evaluation before treatment. Your healthcare provider will review your medical history, current medications, weight management goals, and potential risk factors to determine whether Wegovy is appropriate for you.
Boxed Warning and Contraindications: Wegovy carries a boxed warning regarding thyroid C-cell tumors observed in rodents. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Do not use Wegovy if you have a personal or family history of MTC, have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or have experienced a serious allergic reaction to semaglutide or any of the medications ingredients.
Common Side Effects: Frequently reported side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, and other digestive symptoms. These effects may occur during treatment initiation or dose increases. Contact your healthcare provider if symptoms become severe or persistent.
Warnings and Precautions: Serious risks may include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, and allergic reactions. Patients using insulin or certain diabetes medications may have an increased risk of low blood sugar. Inform your healthcare provider about all medical conditions, medications, and upcoming procedures requiring anesthesia or deep sedation.
Medication Interactions: Wegovy should not be used with other semaglutide-containing medications or other GLP-1 receptor agonists. Because semaglutide delays gastric emptying, it may affect the absorption of certain oral medications. Discuss all prescription drugs, over-the-counter medications, vitamins, and supplements with your healthcare provider.
Pregnancy and Reproductive Health: Wegovy should not be used for weight management during pregnancy. Patients planning pregnancy should discuss stopping semaglutide at least two months before attempting to conceive. Notify your healthcare provider immediately if pregnancy occurs during treatment.
Take Wegovy Tablets exactly as prescribed by your licensed healthcare provider. Treatment typically begins with a lower dosage that is gradually increased according to the approved dosing schedule to help improve gastrointestinal tolerability. Take the medication consistently and follow all administration instructions. Do not exceed your prescribed dose or make changes to your treatment without consulting your healthcare provider.
Wegovy works best as part of a comprehensive weight management program that includes balanced nutrition, appropriate physical activity, and ongoing medical guidance. Your healthcare provider may recommend dietary changes, exercise goals, and periodic follow-up appointments to monitor progress, evaluate side effects, and determine whether adjustments to your treatment plan are necessary.
Store Wegovy Tablets according to the manufacturers instructions and the prescription label. Keep tablets in their original packaging, protected from moisture, and out of reach of children and pets. Do not use medication after its expiration date. Consult your pharmacist about the proper disposal of unused or expired tablets. Never share prescription medication with another person.
